作者: Joseph V Pergolizzi Jr , Robert B Raffa
DOI: 10.2147/JPR.S231948
关键词:
摘要: Background Chronic pain is associated with decreased quality of life and one the most common reasons adults seek medical care, making treatment imperative for many aspects patient well-being. management typically involves use Schedule II full μ-opioid receptor agonists relief; however, increasing prevalence opioid addiction a national crisis that impacting public health social economic welfare. Buprenorphine III partial agonist an equally effective but potentially safer option chronic than agonists. The purpose this review to provide overview clinical efficacy safety transdermal buccal formulations buprenorphine, which are approved by Food Drug Administration pain, compared extended-release Methods Controlled or randomized controlled trial information was retrieved from EMBASE, Medline, PubMed using search terms "buprenorphine" AND "chronic" "pain." Results A total 33 studies were ultimately used in review, including 29 (88%) on buprenorphine 4 (12%) film. Although measure intensity varied among studies, each these trials demonstrated relief. 28 also assessed safety, concluding generally well tolerated. Conclusion Comparison current data along results responder analyses support over preferential pain; head-to-head warranted.